LXRX News and Press, Lexicon Pharmaceuticals Inc. From 03/11/24

2024-03-11 11:52:44 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value Lexicon Pharmaceuticals: Navigatin...

2024-03-11 10:00:56 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...

Commercial launch of INPEFA ® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of LX9211 in Diabetic Peripheral Neuropathic Pain...

THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private investment in public equity financin...

Preparations Underway for Resubmission of New Drug Application for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in Patients with Type 1 Diabetes and Chronic Kidney Disease Resubmission is Anticipated Mid-2024 THE WOODLANDS, Texas, March 11, 2024 (GLOBE...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

2024-01-26 10:31:26 ET Summary Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for heart failure, and this could become a more signi...

-INPEFA ® Launch Positioned for Acceleration in 2024- -Clinical Data and FDA Feedback Support INPEFA Life Cycle Management Opportunity in Hypertrophic Cardiomyopathy- -LX9211 Late-Stage Development Underway, with Potential to Be First New Non-Opioid Dr...

2024-01-04 13:03:42 ET Summary LXRX is ~60% of its May highs, despite holding an FDA-approved key drug, Inpefa, in its portfolio. The sell-off can be largely attributed to concerns over Inpefa’s market uptake amid a perfect storm of competition from pharma heavyweights like...

2024-01-01 01:27:26 ET Summary Lexicon Pharmaceuticals faces a critical phase with FDA-approved Inpefa, competing against established drugs like Jardiance. Financially stable short-term, Lexicon grapples with high marketing costs and rapid cash burn, raising long-term sustainabili...